SCHEMBL69725

SCHEMBL69725

CCOC(=O)C(=O)CC(=O)c1ccccc1OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SGMS2 Q8NHU3 3/20 0.52
ABCB1 P08183 1/20 0.52
ALDH1A1 P00352 2/20 0.50
NPC1 O15118 1/20 0.50
NR1H4 Q96RI1 1/20 0.50
HTT P42858 1/20 0.50
PPIA P62937 1/20 0.49
GAA P10253 1/20 0.49
PTGER1 P34995 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
BRD4 O60885 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30535266 1.00 SGMS2 (0.52) SGMS2ABCB1ALDH1A1NPC1NR1H4
SCHEMBL27188704 0.88 LRRK2 (0.50) SGMS2ALDH1A1NPC1NR1H4HTT
SCHEMBL1043101 0.88 FFAR4 (0.52) ALDH1A1NPC1NR1H4PPIALMNA
SCHEMBL4879716 0.88 SGMS2 (0.56) SGMS2ALDH1A1NPC1HTTGAA
SCHEMBL26666325 0.88 LRRK2 (0.52) SGMS2ALDH1A1NPC1NR1H4PTGER1
SCHEMBL7911106 0.88 ALDH1A1 (0.55) ALDH1A1NPC1NR1H4MEN1KMT2A
SCHEMBL377080 0.86 ABCB1 (0.61) SGMS2ABCB1ALDH1A1NPC1NR1H4
SCHEMBL27188479 0.86 PTGER1 (0.52) PTGER1KMT2A
SCHEMBL6947857 0.83 SGMS2 (0.60) SGMS2ALDH1A1NPC1HTTGAA
SCHEMBL2944769 0.83 ALDH1A1 (0.47) ABCB1ALDH1A1NPC1NR1H4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-05-08 US disclosed
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2025-02-25 US disclosed
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof ACCENT THERAPEUTICS, INC. (US) 2024-12-10 US disclosed
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-09-26 US disclosed
US-20240279210-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2024-08-22 US disclosed
WO-2023154519-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-17 WO disclosed
WO-2023154519-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-17 WO disclosed
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed
US-6211234-B1 BENZONITRILE COMPOUNDS WITH ETHER AND SULFIDE GROUPS WITH CARBOXY ACID RHONE-POULENC RORER LIMITED (GB) 2001-04-03 US disclosed
EP-0728128-B1 SUBSTITUTED PHENYL COMPOUNDS RHONE POULENC RORER LTD (GB) 1998-09-16 EP disclosed
EP-0728128-A1 SUBSTITUTED PHENYL COMPOUNDS RHONE-POULENC RORER LIMITED (GB) 1996-08-28 EP disclosed
WO-1995013262-A1 SUBSTITUTED PHENYL COMPOUNDS RHONE-POULENC RORER LIMITED (GB) 1995-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316047-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B SGMS2 4133/4885ABCB1 731/4885ALDH1A1 1705/4885
US-20240279210-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX29, DHX9, DDX39B SGMS2 3774/4885ABCB1 904/4885ALDH1A1 1333/4885
US-12233065-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B SGMS2 4133/4885ABCB1 731/4885ALDH1A1 1705/4885
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 SGMS2 63/4885ABCB1 2392/4885ALDH1A1 784/4885
US-12162867-B2 Inhibitors of RNA helicase DHX9 and uses thereof DHX29, DHX9, DDX39B SGMS2 3774/4885ABCB1 904/4885ALDH1A1 1333/4885
US-20250145597-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B SGMS2 4112/4885ABCB1 925/4885ALDH1A1 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.